Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. (DNTH) Stock Overview

Explore Dianthus Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

DNTH●NASDAQ
HealthcareBiotechnology
$89.30
$0.49(0.55%)
U.S. Market opens in 4h 0m

Dianthus Therapeutics, Inc. (DNTH)

Meyka AI Score

Z

Key Financials

Market Cap5B
P/E Ratio2980.00
EPS (TTM)$-4.15
ROE-0.04%
Fundamental Analysis

AI Price Forecasts

1 Month$95.07
3 Months$125.72
1 Year Target$98.69

DNTH Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Dianthus Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of DNTH on the NASDAQ shows an RSI of 59.62, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $98.69 for the NASDAQ listing.

Key metrics behind Dianthus Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 2980.00 and a market capitalization of 5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DNTH on the NASDAQ.

Price Performance (NASDAQ: DNTH)

1-Day Change
0.55%
5-Day Change
6.16%
1-Month Change
8.41%
3-Month Change
-17.69%
6-Month Change
2.50%
Year-to-Date (YTD) Change
116.69%
1-Year Change
147.37%
3-Year Change
686.78%
5-Year Change
-24.88%
All-Time (Max) Change
-61.56%

Contact Information

https://dianthustx.com
929-999-4055
7 Times Square, New York, NY, 10036

Company Facts

920 Employees
IPO DateJun 21, 2018
CountryUS
Actively Trading

Frequently Asked Questions